zenofor sr 1000 mg tabletki o przedłużonym uwalnianiu
zentiva, k.s. - metformini hydrochloridum - tabletki o przedłużonym uwalnianiu - 1000 mg
zenofor sr 500 mg tabletki o przedłużonym uwalnianiu
zentiva, k.s. - metformini hydrochloridum - tabletki o przedłużonym uwalnianiu - 500 mg
zenofor sr 750 mg tabletki o przedłużonym uwalnianiu
zentiva, k.s. - metformini hydrochloridum - tabletki o przedłużonym uwalnianiu - 750 mg
agartha duo 50 mg + 850 mg tabletki powlekane
gedeon richter polska sp. z o.o. - vildagliptinum + metformini hydrochloridum - tabletki powlekane - 50 mg + 850 mg
agartha duo 50 mg + 1000 mg tabletki powlekane
gedeon richter polska sp. z o.o. - vildagliptinum + metformini hydrochloridum - tabletki powlekane - 50 mg + 1000 mg
sitagliptin / metformin hydrochloride mylan
mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - diabetes mellitus, type 2 - leki stosowane w cukrzycy - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. potrójnej terapii skojarzonej), jako uzupełnienie diety i ćwiczeń fizycznych u pacjentów niedostatecznie kontrolowanych o ich maksymalnej tolerowanej dawki sulfonylomocznika z metforminą i. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.
ipinzan 50 mg + 850 mg tabletki powlekane
zentiva, k.s. - vildagliptinum + metformini hydrochloridum - tabletki powlekane - 50 mg + 850 mg
ipinzan 50 mg + 1000 mg tabletki powlekane
zentiva, k.s. - vildagliptinum + metformini hydrochloridum - tabletki powlekane - 50 mg + 1000 mg
juzimette 50 mg + 1000 mg tabletki powlekane
gedeon richter polska sp. z o.o. - sitagliptinum + metformini hydrochloridum - tabletki powlekane - 50 mg + 1000 mg
juzimette 50 mg + 850 mg tabletki powlekane
gedeon richter polska sp. z o.o. - sitagliptinum + metformini hydrochloridum - tabletki powlekane - 50 mg + 850 mg